Arbutus Biopharma
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Arbutus Biopharma generated cash of -$85,936,000, which is less than the previous year. Cash used in financing activities reached the amount of $30,647,000 last year. Net change in cash is therefore -$4,491,000.
Cash Flow
| 2014 | -12.42M | -42.95M | 60.67M |
|---|---|---|---|
| 2015 | -54.78M | 7.68M | 143.87M |
| 2016 | -57.88M | -99.12M | 12.63M |
| 2017 | -48.6M | 27.8M | 49.3M |
| 2018 | -67.9M | -4.1M | 55.6M |
| 2019 | -71.00M | 28.33M | 37.45M |
| 2020 | -51.44M | -14.90M | 86.74M |
| 2021 | -67.53M | -12.67M | 137.23M |
| 2022 | -35.35M | -74.94M | 31.81M |
| 2023 | -85.93M | 50.77M | 30.64M |
ABUS Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 30.77M | 109.28M | 52.25M | 31.79M | 36.94M | 54.3M | 23.4M | 166.77M | 72.18M | 68.71M |
Operating activities | ||||||||||
Net income | -72.84M | -69.45M | -76.24M | -63.74M | -153.72M | -57.1M | -84.4M | -384.16M | -61.12M | -38.83M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 1.40M | 1.42M | 1.75M | 1.97M | 2.02M | 2.18M | 2.02M | 1.09M | 589K | 529K |
Stock-based compensation expense | 9.30M | 7.18M | 6.42M | 6.16M | 6.79M | 0 | 15.11M | 39.15M | 22.09M | 3.28M |
| Deferred income tax benefit | 9.30M | 7.18M | 6.42M | 6.16M | 6.79M | 0 | 15.11M | 39.15M | 22.09M | 3.28M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -424K | -453K | 413K | -108K | 227K | -1.02M | -129K | 735K | 628K | -1.88M |
Inventories | 6.18M | 0 | -1.91M | 0 | 0 | 762K | -880K | -162K | 320K | -1.18M |
Accounts payable | -5.75M | 5.21M | 1.91M | 1.66M | -2.41M | -1.26M | 736K | 26K | -2.48M | 6.25M |
Cash generated by operating activities | -85.93M | -35.35M | -67.53M | -51.44M | -71.00M | -67.9M | -48.6M | -57.88M | -54.78M | -12.42M |
Investing activities | ||||||||||
Purchases Of Investments | -80.50M | -130.43M | -82.21M | -85.57M | -58.75M | -3.01M | 0 | -95.15M | 0 | -41.98M |
Investments In Property Plant And Equipment | -1.00M | -512K | -809K | -229K | -589K | -1.13M | -7.26M | -3.99M | -2.28M | -1.05M |
Acquisitions Net | 0 | 458K | 1.80M | -2.5M | 11K | 25K | 3K | 25K | 324K | 0 |
Cash generated by investing activities | 50.77M | -74.94M | -12.67M | -14.90M | 28.33M | -4.1M | 27.8M | -99.12M | 7.68M | -42.95M |
Financing activities | ||||||||||
Common Stock Issued | 29.85M | 20.32M | 134.66M | 86.29M | 18.60M | 67.64M | 49.32M | 637K | 142.17M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | -11.14M | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | -12.00M | 0 | -12.00M | 0 | 0 |
Cash used in financing activities | 30.64M | 31.81M | 137.23M | 86.74M | 37.45M | 55.6M | 49.3M | 12.63M | 143.87M | 60.67M |
Net Change In Cash | -4.49M | -78.50M | 57.03M | 20.45M | -5.14M | -17.4M | 30.9M | -143.36M | 94.59M | 3.47M |
Cash at end of period | 26.28M | 30.77M | 109.28M | 52.25M | 31.79M | 36.9M | 54.3M | 23.41M | 166.77M | 72.18M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |